Pulmonx Corp

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenue	$22,756	$23,859	$43,342	$46,397
Cost of goods sold	5,014	6,655	9,556	12,851
Gross profit	17,742	17,204	33,786	33,546
Operating expenses
Research and development	5,034	5,306	9,933	10,062
Selling, general and administrative	21,765	26,702	45,866	52,851
Total operating expenses	26,799	32,008	55,799	62,913
Loss from operations	(9,057)	(14,804)	(22,013)	(29,367)
Interest income	329	723	679	1,587
Interest expense	(1,218)	(799)	(2,194)	(1,580)
Other (expense) income, net	(1)	(116)	76	51
Net loss before tax	(9,947)	(14,996)	(23,452)	(29,309)
Income tax expense	133	177	282	312
Net loss	(10,080)	(15,173)	(23,734)	(29,621)
Other comprehensive (loss) income
Currency translation adjustment	(120)	435	(311)	546
Change in unrealized losses on marketable securities	—	(1)	—	(23)
Total other comprehensive (loss) income	(120)	434	(311)	523
Comprehensive loss	$(10,200)	$(14,739)	$(24,045)	$(29,098)
Net loss per share attributable to common stockholders, basic and diluted	$(0.24)	$(0.38)	$(0.56)	$(0.74)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	42,468,762	40,429,655	42,184,793	40,193,469

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.